Developer docs
API playgroundTry for free, no card

Search company profiles

ADEL

Full company profile

uuid0002slf

Namestring
ADEL
Legal namestring
주식회사 아델 (ADEL, Inc.)
Websiteurl
adelpharm.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

ADEL (주식회사 아델; ADEL, Inc.) is a South Korea–based clinical-stage biopharmaceutical company founded in November 2016 as a spin-off from the Ulsan College of Medicine at Asan Hospital. The company develops therapeutic antibodies, small-molecule degraders, and diagnostic agents for Alzheimer's disease and other neurodegenerative conditions, with five disclosed pipeline assets: ADEL-Y01 (tau-acK280 monoclonal antibody, Phase 1 in the US), ADEL-Y03 (free β2-microglobulin antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), ADEL-Y07 (ADTAC™-based small-molecule degrader for tau aggregates and androgen receptor, Hit-to-Lead), and ADEL-D01 (tau pT217 diagnostic antibody). ADEL's underlying technology rests on two proprietary platforms: ADTAC™ (Autophagic Degradation Targeting Chimera), which delivers target molecules to LC3 domains for degradation through autophagy and can clear large protein aggregates, lipids, and organelles independent of proteasome or E3-ligase activity; and BTS (Brain Targeting System), which fuses biopharmaceuticals with Brain Penetrating Peptides to optimize blood-brain barrier penetration.

The business model is enterprise licensing and milestone-driven: ADEL develops drug candidates through preclinical and early clinical stages and out-licenses them to global pharmaceutical partners for worldwide development and commercialization, receiving upfront payments, development and commercial milestones, and royalties on net sales. The company's primary commercial validation is a December 2025 licensing agreement with Sanofi for ADEL-Y01 valued at up to $1.04 billion, including an $80 million upfront payment. Recurring operating support includes Korean R&D grants (notably 5.3 billion KRW from Oscotec and the Dementia Overcoming R&D Project Group since May 2023) and venture funding (~30 billion KRW cumulative since 2018, including a 17 billion KRW Series B bridge in August 2024). ADEL employs approximately 20 people across three sites in Seoul and Yongin-si, is led by founder-CEO Seung-Yong Yoon (Chief Professor at Asan Medical Center), and is preparing for a KOSDAQ IPO.

Short descriptiontext

ADEL is a South Korean clinical-stage biopharmaceutical company developing antibody therapies, small-molecule degraders, and diagnostics for Alzheimer's disease and other neurodegenerative conditions, with lead candidate ADEL-Y01 in US Phase 1 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Alzheimer's therapeutics, Monoclonal antibody development, Neurodegenerative disease drug development, Targeted protein degradation, Blood-brain barrier delivery
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Alzheimer's Disease Therapeutics and Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

ADEL generates revenue through licensing deals with pharmaceutical companies. The company receives upfront payments, development and commercial milestone payments, and royalties on net sales. Recent deal with Sanofi for ADEL-Y01 includes $80 million upfront plus up to $960 million in milestones plus royalties.

reuters.com
2R&D Funding
TypeLicensing Royalties
Description

The company receives R&D funding from government and institutional sources. Received 5.3 billion won in R&D funding from Oscotec and the Dementia Overcoming Research and Development Project Group since May 2023.

biz.chosun.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ADTAC™
Description

Autophagic Degradation Targeting Chimera - a platform technology for degrading proteins, lipids, and organelles through autophagy

adelpharm.com
+1 more record
Core offering1 text field

ADEL is a clinical-stage biopharmaceutical company that develops therapeutic antibodies, targeted protein degraders, and diagnostic antibodies for Alzheimer's disease and other neurodegenerative disorders. Its pipeline includes ADEL-Y01 (tau-acK280 monoclonal antibody, Phase 1 in the US), ADEL-Y03 (free β2-microglobulin antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), ADEL-Y07 (ADTAC-based tau degrader, hit-to-lead), and ADEL-D01 (tau pT217 diagnostic antibody). Drug candidates are advanced through clinical milestones and then out-licensed to global pharmaceutical partners for worldwide commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First-in-class tau-acK280 antibody demonstrated superior inhibition of tau seeding and aggregation compared to competing antibodies in preclinical studies
+2 more records
Product overview1 text field

ADEL is a biopharmaceutical company focused on developing treatments and diagnostics for Alzheimer's disease and other neurodegenerative conditions. The company operates two core technology platforms: ADTAC™ (Autophagic Degradation Targeting Chimera) for targeted protein degradation, and BTS (Brain Targeting System) for blood-brain barrier penetration. The therapeutic pipeline includes five drug candidates: ADEL-Y01 (tau antibody, Phase 1), ADEL-Y03 (β2m antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), and ADEL-Y07 (ADTAC-based tau degrader, Hit-to-Lead). Additionally, ADEL-D01 is a diagnostic antibody for Alzheimer's disease detection.

Product and service5 records
1ADEL-Y01
CategoryAlzheimer's disease monoclonal antibody therapeutic
Description

ADEL-Y01 is a humanized monoclonal antibody targeting acetylated tau protein at lysine 280 (acK280) for the treatment of Alzheimer's disease and tauopathies. It inhibits tau aggregation, seeding, and propagation and enhances microglial tau clearance. Currently in Phase 1 clinical trials in the United States following FDA IND approval in Q4 2023, and licensed to Sanofi in December 2025 for worldwide development and commercialization.

2ADEL-Y03
CategoryAnti-aging / anti-inflammatory monoclonal antibody therapeutic
Description

ADEL-Y03 is a monoclonal antibody selectively recognizing MHC-I-free β2-microglobulin (free-β2m), a systemic pro-aging factor that impairs cognitive function. It is being developed for Alzheimer's disease, aging-related cognitive decline, fibrosis (kidney, liver, lung), cancer, and inflammation, and is currently in preclinical efficacy stage.

3ADEL-Y04
CategoryGenetic risk factor-targeting monoclonal antibody therapeutic
Description

ADEL-Y04 is a monoclonal antibody targeting Apolipoprotein E4 (ApoE4), the strongest genetic risk factor for Alzheimer's disease (two copies increase AD risk by up to 12 times). It is being developed for Alzheimer's disease and metabolic disease indications, and is currently in preclinical efficacy stage.

4ADEL-Y07 (ADTAC™)
CategoryTargeted protein degradation small molecule
Description

ADEL-Y07 is a small-molecule therapeutic candidate built on ADEL's ADTAC™ (Autophagic Degradation Targeting Chimera) platform. It targets tau aggregates for Alzheimer's disease and the androgen receptor for prostate cancer, and is currently in hit-to-lead discovery stage.

5ADEL-D01
CategoryAlzheimer's disease diagnostic antibody
Description

ADEL-D01 is a monoclonal antibody recognizing phosphorylated tau at threonine 217 (pT217), a highly specific biomarker for detecting preclinical and advanced Alzheimer's disease, dementia, and tauopathies. It is being developed as a diagnostic product for Alzheimer's disease detection.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Sanofi entered into a licensing and development collaboration with ADEL for ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease. Total potential deal value up to $1.04 billion. ADEL receives $80 million upfront non-refundable payment plus development and commercial milestone payments and tiered royalties up to double-digit percentages on net sales. Sanofi receives worldwide development and commercialization rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner for drug development since 2020. Contract signed for joint development of Alzheimer's disease treatments including ADEL-Y01. Oscotec has co-developed the tau antibody candidate with ADEL since 2020. Oscotec also provided R&D funding to ADEL.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ADEL is a spin-off company from Ulsan University College of Medicine at Asan Hospital. The company maintains close ties with the institution, with CEO Yoon Seung-Yong serving as Chief Professor at the Department of Brain Science, Asan Medical Center.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

ADEL was selected as a finalist in the Johnson & Johnson Innovation JLABS program in March 2025, providing potential access to J&J's resources and ecosystem.

5KITE (Korea Institute of Toxicology)
Strategic tierSupportingTypeTechnology or Integration
Description

Listed as a partner in ADEL's ecosystem for toxicology research and development support.

adelpharm.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Developer of Leqembi (lecanemab), an FDA-approved anti-amyloid antibody for Alzheimer's disease. Directly comparable because Biogen competes in the same neurodegenerative antibody therapeutics space ADEL targets, albeit at a vastly larger scale and with an amyloid-focused mechanism.

TypeBroad incumbent
Description

Developer of Kisunla (donanemab), another FDA-approved anti-amyloid Alzheimer's antibody. Lilly is a relevant incumbent peer because it validates the commercial Alzheimer's antibody market ADEL is pursuing with its tau-targeted approach.

TypeDirect peer
Description

Clinical-stage biotech developing tau-targeting antibodies for Alzheimer's and other neurodegenerative diseases. Most directly comparable to ADEL because both companies are building pipelines around disease-modifying anti-tau antibodies targeting post-translational modifications.

TypeDirect peer
Description

Swiss clinical-stage biotech developing both active immunotherapies (vaccines) and passive antibodies against tau and amyloid for Alzheimer's disease. Comparable to ADEL as a similarly-sized peer developing tau-focused therapeutics, including a Morphomer tau aggregation inhibitor program.

5Eisai
TypeDirect peer
Description

Co-developer of Leqembi (lecanemab) and a major Alzheimer's-focused pharma. Relevant peer because of its deep commitment to neurodegenerative disease pipelines and as a potential comparator/licensor for tau antibody programs similar to ADEL-Y01.

TypeBroad incumbent
Description

Developed gantenerumab (anti-amyloid) for Alzheimer's and runs broader CNS/neurodegenerative programs. Comparable as a large incumbent pursuing disease-modifying antibody therapeutics in the same indication space ADEL targets.

TypeEmerging player
Description

Clinical-stage biotech developing small-molecule therapies (e.g., fosgonimeton) targeting HGF/MET signaling for Alzheimer's and other neurodegenerative diseases. Comparable as a similarly-sized emerging peer developing non-amyloid Alzheimer's mechanisms.

TypeEmerging player
Description

Clinical-stage biotech developing sigma-1 receptor agonists (blarcamesine) for Alzheimer's disease and other neurological indications. Comparable as a small-cap peer pursuing disease-modifying Alzheimer's mechanisms outside the dominant amyloid hypothesis.

9Cassava Sciences
TypeEmerging player
Description

Clinical-stage biotech developing simufilam for Alzheimer's disease, a small-molecule targeting filamin A. Comparable as a small-cap peer pursuing novel, non-amyloid Alzheimer's mechanisms with similar regulatory and clinical risk profile.

TypeRegional player
Description

South Korean biotech that has been ADEL's co-development partner for the tau antibody program since 2020 and a provider of R&D funding. Comparable as a regional peer with overlapping neuroscience drug development activities and as a direct operational partner.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ADEL

Alzheimer's Disease Therapeutics and Diagnosticsadelpharm.com

ADEL is a South Korean clinical-stage biopharmaceutical company developing antibody therapies, small-molecule degraders, and diagnostics for Alzheimer's disease and other neurodegenerative conditions, with lead candidate ADEL-Y01 in US Phase 1 trials.

What ADEL does

ADEL (주식회사 아델; ADEL, Inc.) is a South Korea–based clinical-stage biopharmaceutical company founded in November 2016 as a spin-off from the Ulsan College of Medicine at Asan Hospital. The company develops therapeutic antibodies, small-molecule degraders, and diagnostic agents for Alzheimer's disease and other neurodegenerative conditions, with five disclosed pipeline assets: ADEL-Y01 (tau-acK280 monoclonal antibody, Phase 1 in the US), ADEL-Y03 (free β2-microglobulin antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), ADEL-Y07 (ADTAC™-based small-molecule degrader for tau aggregates and androgen receptor, Hit-to-Lead), and ADEL-D01 (tau pT217 diagnostic antibody). ADEL's underlying technology rests on two proprietary platforms: ADTAC™ (Autophagic Degradation Targeting Chimera), which delivers target molecules to LC3 domains for degradation through autophagy and can clear large protein aggregates, lipids, and organelles independent of proteasome or E3-ligase activity; and BTS (Brain Targeting System), which fuses biopharmaceuticals with Brain Penetrating Peptides to optimize blood-brain barrier penetration.

The business model is enterprise licensing and milestone-driven: ADEL develops drug candidates through preclinical and early clinical stages and out-licenses them to global pharmaceutical partners for worldwide development and commercialization, receiving upfront payments, development and commercial milestones, and royalties on net sales. The company's primary commercial validation is a December 2025 licensing agreement with Sanofi for ADEL-Y01 valued at up to $1.04 billion, including an $80 million upfront payment. Recurring operating support includes Korean R&D grants (notably 5.3 billion KRW from Oscotec and the Dementia Overcoming R&D Project Group since May 2023) and venture funding (~30 billion KRW cumulative since 2018, including a 17 billion KRW Series B bridge in August 2024). ADEL employs approximately 20 people across three sites in Seoul and Yongin-si, is led by founder-CEO Seung-Yong Yoon (Chief Professor at Asan Medical Center), and is preparing for a KOSDAQ IPO.

ADEL firmographics

Firmographics
Name
ADEL
Legal name
주식회사 아델 (ADEL, Inc.)
Website
https://adelpharm.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
ADEL is a South Korean clinical-stage biopharmaceutical company developing antibody therapies, small-molecule degraders, and diagnostics for Alzheimer's disease and other neurodegenerative conditions, with lead candidate ADEL-Y01 in US Phase 1 trials.
Ownership category
akta.pro rank

ADEL industry classification

Industry
Product category
Alzheimer's Disease Therapeutics and Diagnostics
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Alzheimer's therapeutics
  • Monoclonal antibody development
  • Neurodegenerative disease drug development
  • Targeted protein degradation
  • Blood-brain barrier delivery

Where ADEL is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

ADEL business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Licensing and Milestone Payments: ADEL generates revenue through licensing deals with pharmaceutical companies. The company receives upfront payments, development and commercial milestone payments, and royalties on net sales. Recent deal with Sanofi for ADEL-Y01 includes $80 million upfront plus up to $960 million in milestones plus royalties.
  2. R&D Funding: The company receives R&D funding from government and institutional sources. Received 5.3 billion won in R&D funding from Oscotec and the Dementia Overcoming Research and Development Project Group since May 2023.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ADEL product offering

Product offering

Core offering

ADEL is a clinical-stage biopharmaceutical company that develops therapeutic antibodies, targeted protein degraders, and diagnostic antibodies for Alzheimer's disease and other neurodegenerative disorders. Its pipeline includes ADEL-Y01 (tau-acK280 monoclonal antibody, Phase 1 in the US), ADEL-Y03 (free β2-microglobulin antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), ADEL-Y07 (ADTAC-based tau degrader, hit-to-lead), and ADEL-D01 (tau pT217 diagnostic antibody). Drug candidates are advanced through clinical milestones and then out-licensed to global pharmaceutical partners for worldwide commercialization.

Product overview

ADEL is a biopharmaceutical company focused on developing treatments and diagnostics for Alzheimer's disease and other neurodegenerative conditions. The company operates two core technology platforms: ADTAC™ (Autophagic Degradation Targeting Chimera) for targeted protein degradation, and BTS (Brain Targeting System) for blood-brain barrier penetration. The therapeutic pipeline includes five drug candidates: ADEL-Y01 (tau antibody, Phase 1), ADEL-Y03 (β2m antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), and ADEL-Y07 (ADTAC-based tau degrader, Hit-to-Lead). Additionally, ADEL-D01 is a diagnostic antibody for Alzheimer's disease detection.

Differentiator

Problem solved

Functional benefit

Brands

  • ADTAC™: Autophagic Degradation Targeting Chimera - a platform technology for degrading proteins, lipids, and organelles through autophagy
  • BTS

Products and services

  • ADEL-Y01 ADEL-Y01 is a humanized monoclonal antibody targeting acetylated tau protein at lysine 280 (acK280) for the treatment of Alzheimer's disease and tauopathies. It inhibits tau aggregation, seeding, and propagation and enhances microglial tau clearance. Currently in Phase 1 clinical trials in the United States following FDA IND approval in Q4 2023, and licensed to Sanofi in December 2025 for worldwide development and commercialization.
  • ADEL-Y03 ADEL-Y03 is a monoclonal antibody selectively recognizing MHC-I-free β2-microglobulin (free-β2m), a systemic pro-aging factor that impairs cognitive function. It is being developed for Alzheimer's disease, aging-related cognitive decline, fibrosis (kidney, liver, lung), cancer, and inflammation, and is currently in preclinical efficacy stage.
  • ADEL-Y04 ADEL-Y04 is a monoclonal antibody targeting Apolipoprotein E4 (ApoE4), the strongest genetic risk factor for Alzheimer's disease (two copies increase AD risk by up to 12 times). It is being developed for Alzheimer's disease and metabolic disease indications, and is currently in preclinical efficacy stage.
  • ADEL-Y07 (ADTAC™) ADEL-Y07 is a small-molecule therapeutic candidate built on ADEL's ADTAC™ (Autophagic Degradation Targeting Chimera) platform. It targets tau aggregates for Alzheimer's disease and the androgen receptor for prostate cancer, and is currently in hit-to-lead discovery stage.
  • ADEL-D01 ADEL-D01 is a monoclonal antibody recognizing phosphorylated tau at threonine 217 (pT217), a highly specific biomarker for detecting preclinical and advanced Alzheimer's disease, dementia, and tauopathies. It is being developed as a diagnostic product for Alzheimer's disease detection.

Quantifiable outcome

  • First-in-class tau-acK280 antibody demonstrated superior inhibition of tau seeding and aggregation compared to competing antibodies in preclinical studies
  • +2 more outcomes

Companies that use ADEL

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

ADEL technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ADEL partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and supporting.

  • SanofiflagshipStrategic or Co-development Partner · 15 December 2025Sanofi entered into a licensing and development collaboration with ADEL for ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease. Total potential deal value up to $1.04 billion. ADEL receives $80 million upfront non-refundable payment plus development and commercial milestone payments and tiered royalties up to double-digit percentages on net sales. Sanofi receives worldwide development and commercialization rights.
  • Oscotec, Inc.coreStrategic or Co-development PartnerCo-development partner for drug development since 2020. Contract signed for joint development of Alzheimer's disease treatments including ADEL-Y01. Oscotec has co-developed the tau antibody candidate with ADEL since 2020. Oscotec also provided R&D funding to ADEL.
  • Asan Medical Center / Ulsan University College of MedicinecoreStrategic or Co-development PartnerADEL is a spin-off company from Ulsan University College of Medicine at Asan Hospital. The company maintains close ties with the institution, with CEO Yoon Seung-Yong serving as Chief Professor at the Department of Brain Science, Asan Medical Center.
  • Johnson & Johnson InnovationsupportingStrategic or Co-development PartnerADEL was selected as a finalist in the Johnson & Johnson Innovation JLABS program in March 2025, providing potential access to J&J's resources and ecosystem.
  • KITE (Korea Institute of Toxicology)supportingTechnology or IntegrationListed as a partner in ADEL's ecosystem for toxicology research and development support.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

ADEL competitors and assessment

Company assessment

Broad incumbents

  • Biogen: Developer of Leqembi (lecanemab), an FDA-approved anti-amyloid antibody for Alzheimer's disease. Directly comparable because Biogen competes in the same neurodegenerative antibody therapeutics space ADEL targets, albeit at a vastly larger scale and with an amyloid-focused mechanism.
  • Eli Lilly: Developer of Kisunla (donanemab), another FDA-approved anti-amyloid Alzheimer's antibody. Lilly is a relevant incumbent peer because it validates the commercial Alzheimer's antibody market ADEL is pursuing with its tau-targeted approach.
  • Roche: Developed gantenerumab (anti-amyloid) for Alzheimer's and runs broader CNS/neurodegenerative programs. Comparable as a large incumbent pursuing disease-modifying antibody therapeutics in the same indication space ADEL targets.

Direct peers

  • Prothena: Clinical-stage biotech developing tau-targeting antibodies for Alzheimer's and other neurodegenerative diseases. Most directly comparable to ADEL because both companies are building pipelines around disease-modifying anti-tau antibodies targeting post-translational modifications.
  • AC Immune: Swiss clinical-stage biotech developing both active immunotherapies (vaccines) and passive antibodies against tau and amyloid for Alzheimer's disease. Comparable to ADEL as a similarly-sized peer developing tau-focused therapeutics, including a Morphomer tau aggregation inhibitor program.
  • Eisai: Co-developer of Leqembi (lecanemab) and a major Alzheimer's-focused pharma. Relevant peer because of its deep commitment to neurodegenerative disease pipelines and as a potential comparator/licensor for tau antibody programs similar to ADEL-Y01.

Emerging players

  • Athira Pharma: Clinical-stage biotech developing small-molecule therapies (e.g., fosgonimeton) targeting HGF/MET signaling for Alzheimer's and other neurodegenerative diseases. Comparable as a similarly-sized emerging peer developing non-amyloid Alzheimer's mechanisms.
  • Anavex Life Sciences: Clinical-stage biotech developing sigma-1 receptor agonists (blarcamesine) for Alzheimer's disease and other neurological indications. Comparable as a small-cap peer pursuing disease-modifying Alzheimer's mechanisms outside the dominant amyloid hypothesis.
  • Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease, a small-molecule targeting filamin A. Comparable as a small-cap peer pursuing novel, non-amyloid Alzheimer's mechanisms with similar regulatory and clinical risk profile.

Regional players

  • Oscotec: South Korean biotech that has been ADEL's co-development partner for the tau antibody program since 2020 and a provider of R&D funding. Comparable as a regional peer with overlapping neuroscience drug development activities and as a direct operational partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ADEL social profiles

Digital presence

ADEL financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ADEL leadership team

Management profile

Number of profiles

Profiles1 record

ADEL funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ADEL M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADEL

What does ADEL do?

ADEL is a clinical-stage biopharmaceutical company that develops therapeutic antibodies, targeted protein degraders, and diagnostic antibodies for Alzheimer's disease and other neurodegenerative disorders. Its pipeline includes ADEL-Y01 (tau-acK280 monoclonal antibody, Phase 1 in the US), ADEL-Y03 (free β2-microglobulin antibody, preclinical), ADEL-Y04 (ApoE4 antibody, preclinical), ADEL-Y07 (ADTAC-based tau degrader, hit-to-lead), and ADEL-D01 (tau pT217 diagnostic antibody). Drug candidates are advanced through clinical milestones and then out-licensed to global pharmaceutical partners for worldwide commercialization.

Is ADEL a public or private company?

ADEL is a private company. It is classified as venture growth investor backed and is currently operating.

When was ADEL founded?

ADEL was founded in 2016. It employs 1 to 10 people.

Where is ADEL based?

ADEL is headquartered in Seoul, South Korea, in the Asia region.

How does ADEL make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are R&D Funding.

Who are ADEL's main competitors?

Broad incumbents on record are Biogen, Eli Lilly and Roche. Direct peers are Prothena, AC Immune and Eisai. Emerging players are Athira Pharma, Anavex Life Sciences and Cassava Sciences. Oscotec is listed as a regional player.

Does ADEL have an API?

No public API is recorded for ADEL.

What industry is ADEL in?

ADEL's product category is Alzheimer's Disease Therapeutics and Diagnostics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate[단독] 오스코텍, ADEL-Y01 1상 종료…후속 기술료 시점 안갯속 : 네이트 뉴스Oscotec's Phase 1a/1b trial of ADEL-Y01, an Alzheimer's drug co-developed with Adel and licensed to Sanofi, ended on April 30, though the company's semi-annual report still lists it as "in Phase 1." Sanofi's new trial schedule, including patient numbers and first-dosing timing, has not been disclosed. Oscotec's milestone royalties, tied to clinical, approval and commercialization, remain undisclosed.VenturesquareThe Alzheimer's new drug chosen by Sanofi... Adele, with the successful completion of the technology assessment, is accelerating its IPO.Adele, a biotech developing Alzheimer's drugs, passed KOSDAQ technology listing evaluation with A and BBB grades, entering IPO. It plans to file for preliminary review, with Mirae Asset and Samsung Securities as underwriters. The company also secured a $1.04 billion technology transfer deal with Sanofi.EdailyAdele, successful in winning government R&D projects one after anotherADEL secured two government R&D projects totaling 3.7 billion won over three years, including a 1.5 billion won TIPS project and a 2.2 billion won health project. The funding supports development of a brain delivery platform and ApoE4-targeting antibody ADEL-Y04. The company also plans a KOSDAQ listing with Samsung and Mirae Asset as underwriters.VenturesquareAdel, which has won consecutive government R&D contracts, accelerates the development of next-generation dementia drugs.Adel, a dementia drug developer, won two consecutive government R&D contracts, including a TIPS Deep Tech Track and a Health and Welfare Ministry project. It will receive 1.5 billion won for a brain delivery platform and 2.2 billion won for ApoE4-targeted antibody ADEL-Y04, aiming for Phase 1 clinical trials.ChosunbizRate cuts and patent expirations revive Korea bio IPO marketMultiple South Korean biotech corporations are preparing to list on KOSDAQ in the first quarter after postponing IPOs last year, driven by rate cuts and patent expirations at global pharmaceutical companies. Adel, a biotech firm spun off from Ulsan College of Medicine, is among the leading candidates after out-licensing its Alzheimer's disease treatment candidate to Sanofi for approximately 1.5 trillion won, which helped it overcome last year's failed technology evaluation. Industry analysts estimate patents on 69 global blockbuster drugs will expire by 2030, creating a $256 billion sales gap for Big Pharma and increasing demand for new drug technologies from biotech firms.HomepageADEL Signs $1.04 Billion Licensing Deal with Sanofi for Alzheimer’s Antibody TherapySouth Korean biotech ADEL has entered into an exclusive worldwide license agreement with Sanofi for its investigational Alzheimer’s antibody therapy, ADEL-Y01. The deal is valued at up to $1.04 billion, including an $80 million upfront payment and potential milestone payments plus royalties. ADEL-Y01 is currently in global Phase 1 clinical trials targeting tau protein aggregation.Ts2Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB SlideOn December 16, 2025, U.S. biotech ETFs declined as individual stocks reacted sharply to varied regulatory and clinical catalysts, including Monte Rosa's positive prostate cancer data and Aldeyra's FDA review extension. Simultaneously, major deal activity was reported, with Xoma agreeing to acquire Generation Bio and Sanofi securing two significant partnerships with ADEL and Dren Bio.ReutersSouth Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with SanofiSouth Korea-based ADEL has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and commercialize ADEL's experimental Alzheimer's disease treatment. Under the agreement, ADEL will receive an $80 million upfront payment plus additional milestone payments tied to development progress and royalties on future sales. ADEL's drug candidate ADL-Y01, an antibody therapy targeting tau acetylation, is currently in early-stage human trials in the United States.Global BankingSouth Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with SanofiSouth Korea-based biotech company ADEL signed a $1.04 billion partnership with French drugmaker Sanofi to develop and commercialize ADEL's experimental Alzheimer's disease treatment. Under the deal, ADEL will receive an $80 million upfront payment plus additional milestone payments tied to development progress and royalties on future sales. ADEL's drug candidate ADEL-Y01, an antibody therapy targeting harmful forms of a protein linked to Alzheimer's, is currently in early-stage human trials in the United States.The Korea HeraldAdel clinches $1b Alzheimer’s therapy license deal with SanofiKorean biopharmaceutical company Adel announced a license-out agreement worth up to $1.04 billion with global healthcare firm Sanofi for the development and commercialization of Adel-Y01, a potential Alzheimer's disease therapy. Under the deal, Adel will receive an $80 million upfront payment, additional milestone-based payments, and royalties reaching up to double-digit percentages on net sales of the neurodegenerative disease therapy. Adel-Y01, a humanized monoclonal antibody targeting acetylated tau protein, is currently undergoing a global Phase 1 clinical trial under an FDA-approved investigational new drug application.